Nutrition therapy for liver diseases based on the status of nutritional intake

Gastroenterology Research and Practice

Volumn , Issue , 2012, Pages

  Yasutake, Kenichiro ^a,b   Kohjima, Motoyuki ^b   Nakashima, Manabu ^c   Kotoh, Kazuhiro ^d   Nakamuta, Makoto ^b   Enjoji, Munechika ^b,c  

^a NISHIKYUSHU UNIVERSITY   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION   (Japan)

^c FUKUOKA UNIVERSITY   (Japan)

^d KYUSHU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

IRON;

CHOLESTEROL INTAKE; DIET THERAPY; DIETARY INTAKE; HEPATITIS C; HUMAN; LIPID DIET; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DISEASE; MALNUTRITION; NONALCOHOLIC FATTY LIVER; NUTRITIONAL SUPPORT; PROTEIN INTAKE; QUALITY OF LIFE; REVIEW; SAFETY;

EID: 84871372568     PISSN: 16876121     EISSN: 1687630X     Source Type: Journal    
DOI: 10.1155/2012/859697     Document Type: Review

References (101)

1. Assy N., Nasser G., Kamayse I., Nseir W., Beniashvili Z., Djibre A., Grosovski M., Soft drink consumation linked with fatty liver in the absence of traditional risk factors. Canadian Journal of Gastroenterology 2008 22 10 811 816 2-s2.0-58249086284
2. Ouyang X., Cirillo P., Sautin Y., McCall S., Bruchette J. L., Diehl A. M., Johnson R. J., Abdelmalek M. F., Fructose consumption as a risk factor for non-alcoholic fatty liver disease. Journal of Hepatology 2008 48 6 993 999 2-s2.0-43049170503 10.1016/j.jhep.2008.02.011
3. Abid A., Taha O., Nseir W., Farah R., Grosovski M., Assy N., Soft drink consumption is associated with fatty liver disease independent of metabolic syndrome. Journal of Hepatology 2009 51 5 918 924 2-s2.0-70349738087 10.1016/j.jhep.2009.05.033
4. Toshimitsu K., Matsuura B., Ohkubo I., Niiya T., Furukawa S., Hiasa Y., Kawamura M., Ebihara K., Onji M., Dietary habits and nutrient intake in non-alcoholic steatohepatitis. Nutrition 2007 23 1 46 52 2-s2.0-33845632821 10.1016/j.nut.2006.09.004 (Pubitemid 44959764)
5. Yamazaki T., Nakamori A., Sasaki E., Wada S., Ezaki O., Fish oil prevents sucrose-induced fatty liver but exacerbates high-safflower oil-induced fatty liver in ddY mice. Hepatology 2007 46 6 1779 1790 2-s2.0-37749013583 10.1002/hep.21934
6. Solga S., Alkhuraishe A. R., Clark J. M., Torbenson M., Greenwald A., Diehl A. M., Magnuson T., Dietary composition and nonalcoholic fatty liver disease. Digestive Diseases and Sciences 2004 49 10 1578 1583 2-s2.0-5044234968 10.1023/B:DDAS.0000043367.69470.b7 (Pubitemid 39335538)
7. Musso G., Gambino R., De Michieli F., Cassader M., Rizzetto M., Durazzo M., Fagà E., Silli B., Pagano G., Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. Hepatology 2003 37 4 909 916 2-s2.0-0037382071 10.1053/jhep.2003.50132 (Pubitemid 36397404)
8. Ha S. K., Chae C., Inducible nitric oxide distribution in the fatty liver of a mouse with high fat diet-induced obesity. Experimental Animals 2010 59 5 595 604 2-s2.0-78149418436 10.1538/expanim.59.595
9. Yasutake K., Nakamuta M., Shima Y., Ohyama A., Masuda K., Haruta N., Fujino T., Aoyagi Y., Fukuizumi K., Yoshimoto T., Takemoto R., Miyahara T., Harada N., Hayata F., Nakashima M., Enjoji M., Nutritional investigation of non-obese patients with non-alcoholic fatty liver disease: the significance of dietary cholesterol. Scandinavian Journal of Gastroenterology 2009 44 4 471 477 2-s2.0-67049114700 10.1080/00365520802588133
10. Kainuma M., Fujimoto M., Sekiya N., Tsuneyama K., Cheng C., Takano Y., Terasawa K., Shimada Y., Cholesterol-fed rabbit as a unique model of nonalcoholic, nonobese, non-insulin-resistant fatty liver disease with characteristic fibrosis. Journal of Gastroenterology 2006 41 10 971 980 2-s2.0-33750996121 10.1007/s00535-006-1883-1 (Pubitemid 44741410)
11. Matsuzawa N., Takamura T., Kurita S., Misu H., Ota T., Ando H., Yokoyama M., Honda M., Zen Y., Nakanuma Y., Miyamoto K. I., Kaneko S., Lipid-induced oxidative stress causes steatohepatitis in mice fed an atherogenic diet. Hepatology 2007 46 5 1392 1403 2-s2.0-36348935003 10.1002/hep.21874 (Pubitemid 350155521)
12. Wouters K., van Gorp P. J., Bieghs V., Gijbels M. J., Duimel H., Lütjohann D., Kerksiek A., van Kruchten R., Maeda N., Staels B., van Bilsen M., Shiri-Sverdlov R., Hofker M. H., Dietary cholesterol, rather than liver steatosis, leads to hepatic inflammation in hyperlipidemic mouse models of nonalcoholic steatohepatitis. Hepatology 2008 48 2 474 486 2-s2.0-49649110937 10.1002/hep.22363
13. Higuchi N., Kato M., Shundo Y., Tajiri H., Tanaka M., Yamashita N., Kohjima M., Kotoh K., Nakamuta M., Takayanagi R., Enjoji M., Liver X receptor in cooperation with SREBP-1c is a major lipid synthesis regulator in nonalcoholic fatty liver disease. Hepatology Research 2008 38 11 1122 1129 2-s2.0-53349153430 10.1111/j.1872-034X.2008.00382.x
14. Nakamuta M., Fujino T., Yada R., Yada M., Yasutake K., Yoshimoto T., Harada N., Higuchi N., Kato M., Kohjima M., Taketomi A., Maehara Y., Nakashima M., Kotoh K., Enjoji M., Impact of cholesterol metabolism and the LXR -SREBP-1c pathway on nonalcoholic fatty liver disease. International Journal of Molecular Medicine 2009 23 5 603 608 2-s2.0-67649429268 10.3892/ijmm-00000170
15. Dixon J. B., Bhathal P. S., Hughes N. R., O'Brien P. E., Nonalcoholic fatty liver disease: improvement in liver histological analysis with weight loss. Hepatology 2004 39 6 1647 1654 2-s2.0-2542546652 10.1002/hep.20251 (Pubitemid 38702666)
16. Elias M. C., Parise E. R., Carvalho L. D., Szejnfeld D., Netto J. P., Effect of 6-month nutritional intervention on non-alcoholic fatty liver disease. Nutrition 2010 26 11-12 1094 1099 2-s2.0-77957785801 10.1016/j.nut.2009.09.001
17. Capanni M., Calella F., Biagini M. R., Genise S., Raimondi L., Bedogni G., Svegliati-Baroni G., Sofi F., Milani S., Abbate R., Surrenti C., Casini A., Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: a pilot study. Alimentary Pharmacology and Therapeutics 2006 23 8 1143 1151 2-s2.0-33646882162 10.1111/j.1365-2036.2006.02885.x (Pubitemid 43779354)
18. Hasegawa T., Yoneda M., Nakamura K., Makino I., Terano A., Plasma transforming growth factor- β 1 level and efficacy of -tocopherol in patients with non-alcoholic steatohepatitis: a pilot study. Alimentary Pharmacology and Therapeutics 2001 15 10 1667 1672 2-s2.0-0034799895 10.1046/j.1365-2036.2001.01083.x (Pubitemid 32912411)
19. Kojima S. I., Watanabe N., Numata M., Ogawa T., Matsuzaki S., Increase in the prevalence of fatty liver in Japan over the past 12 years: analysis of clinical background. Journal of Gastroenterology 2003 38 10 954 961 2-s2.0-0344393668 10.1007/s00535-003-1178-8 (Pubitemid 37455782)
20. Nonomura A., Enomoto Y., Takeda M., Tamura T., Kasai T., Yoshikawa T., Nakamine H., Kojima H., Uemura M., Zen Y., Minato H., Clinical and pathological features of non-alcoholic steatohepatitis. Hepatology Research 2005 33 2 116 121 2-s2.0-29144438774 10.1016/j.hepres.2005.09.017 (Pubitemid 41799787)
21. Enjoji M., Machida K., Kohjima M., Kato M., Kotoh K., Matsunaga K., Nakashima M., Nakamuta M., NPC1L1 inhibitor ezetimibe is a reliable therapeutic agent for non-obese patients with nonalcoholic fatty liver disease. Lipids in Health and Disease 2010 9 29 2-s2.0-77955519012
22. Davies J. P., Scott C., Oishi K., Liapis A., Ioannou Y. A., Inactivation of NPC1L1 causes multiple lipid transport defects and protects against diet-induced hypercholesterolemia. Journal of Biological Chemistry 2005 280 13 12710 12720 2-s2.0-16844376244 10.1074/jbc.M409110200
23. Deushi M., Nomura M., Kawakami A., Haraguchi M., Ito M., Okazaki M., Ishii H., Yoshida M., Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome. FEBS Letters 2007 581 29 5664 5670 2-s2.0-36549013633 10.1016/j.febslet.2007.11.023 (Pubitemid 350179776)
24. Ghafoorunissa, Ibrahim A., Rajkumar L., Acharya V., Dietary (n-3) long chain polyunsaturated fatty acids prevent sucrose-induced insulin resistance in rats. Journal of Nutrition 2005 135 11 2634 2638 2-s2.0-31544471650 (Pubitemid 43156606)
25. Teran-Garcia M., Adamson A. W., Yu G., Rufo C., Suchankova G., Dreesen T. D., Tekle M., Clarke S. D., Gettys T. W., Polyunsaturated fatty acid suppression of fatty acid synthase (FASN): evidence for dietary modulation of NF-Y binding to the Fasn promoter by SREBP-1c. Biochemical Journal 2007 402 3 591 600 2-s2.0-33947261702 10.1042/BJ20061722 (Pubitemid 46423896)
26. Patek A. J., Post J., Treatment of cirrhosis of the liver by a nutritious diet and supplements rich in vitamin B complex. Journal of Clinical Investigation 1941 20 5 481 505
27. Iwasa M., Iwata K., Kaito M., Ikoma J., Yamamoto M., Takeo M., Kuroda M., Fujita N., Kobayashi Y., Adachi Y., Efficacy of long-term dietary restriction of total calories, fat, iron, and protein in patients with chronic hepatitis C virus. Nutrition 2004 20 4 368 371 2-s2.0-12144287400 10.1016/j.nut.2003.12.009 (Pubitemid 38388511)
28. Hamer C., The impact of combination therapy with peginterferon alfa-2a and ribavirin on the energy intake and body weight of adult hepatitis C patients. Journal of Human Nutrition and Dietetics 2008 21 5 486 493 2-s2.0-51649122024 10.1111/j.1365-277X.2008.00882.x
29. Fioravante M., Alegre S. M., Marin D. M., Weight loss and resting energy expenditure in patients with chronic hepatitis C before and during standard treatment. Nutrition 2012 28 6 630 634
30. Fried M. W., Side effects of therapy of hepatitis C and their management. Hepatology 2002 36 5, supplement 1 S237 S244 2-s2.0-0036830454 10.1053/jhep.2002.36810 (Pubitemid 35253486)
31. Manns M. P., McHutchison J. G., Gordon S. C., Rustgi V. K., Shiffman M., Reindollar R., Goodman Z. D., Koury K., Ling M. H., Albrecht J. K., Peginterferon alfa-2b plus ribavirin compared with interferonalfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001 358 9286 958 965 2-s2.0-0035934568 10.1016/S0140-6736(01)06102-5 (Pubitemid 32913521)
32. Fried M. W., Shiffman M. L., Reddy K. R., Smith C., Marinos G., Goncales J. F. L., Häussinger D., Diago M., Carosi G., Dhumeaux D., Craxi A., Lin A., Hoffman J., Yu J., Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. The New England Journal of Medicine 2002 347 13 975 982 2-s2.0-0037179698 10.1056/NEJMoa020047
33. Hayashi H., Takikawa T., Nishimura N., Yano M., Isomura T., Sakamoto N., Improvement of serum aminotransferase levels after phlebotomy in patients with chronic active hepatitis C and excess hepatic iron. American Journal of Gastroenterology 1994 89 7 986 988 2-s2.0-0028318340 (Pubitemid 24201831)
34. Iwasa M., Kaito M., Ikoma J., Kobayashi Y., Tanaka Y., Higuchi K., Takeuchi K., Iwata K., Watanabe S., Adachi Y., Dietary iron restriction improves aminotransferase levels in chronic hepatitis C patients. Hepato- Gastroenterology 2002 49 44 529 531 2-s2.0-0036016518 (Pubitemid 34606588)
35. Yano M., Hayashi H., Wakusawa S., Sanae F., Takikawa T., Shiono Y., Arao M., Ukai K., Ito H., Watanabe K., Yoshioka K., Long term effects of phlebotomy on biochemical and histological parameters of chronic hepatitis C. American Journal of Gastroenterology 2002 97 1 133 137 2-s2.0-0036140561 10.1016/S0002-9270(01)03998-3 (Pubitemid 34059776)
36. Shintani Y., Fujie H., Miyoshi H., Tsutsumi T., Tsukamoto K., Kimura S., Moriya K., Koike K., Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology 2004 126 3 840 848 2-s2.0-1542287381 10.1053/j.gastro.2003.11. 056 (Pubitemid 38298332)
37. Bach N., Thung S. N., Schaffner F., The histological features of chronic hepatitis C and autoimmune chronic hepatitis: a comparative analysis. Hepatology 1992 15 4 572 577 2-s2.0-0026514433
38. Lefkowitch J. H., Schiff E. R., Davis G. L., Perrillo R. P., Lindsay K., Bodenheimer H. C., Balart L. A., Ortego T. J., Payne J., Dienstag J. L., Gibas A., Jacobson I. M., Tamburro C. H., Carey W., O'Brien C., Sampliner R., Van Thiel D. H., Feit D., Albrecht J., Pathological diagnosis of chronic hepatitis C: a multicenter comparative study with chronic hepatitis B. Gastroenterology 1993 104 2 595 603 2-s2.0-0027386603 (Pubitemid 23033436)
39. Romero-Gómez M., Del Mar Viloria M., Andrade R. J., Salmerón J., Diago M., Fernández-Rodríguez C. M., Corpas R., Cruz M., Grande L., Vázquez L., Muñoz-De-Rueda P., López-Serrano P., Gila A., Gutiérrez M. L., Pérez C., Ruiz-Extremera A., Suárez E., Castillo J., Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005 128 3 636 641 2-s2.0-15744381704 10.1053/j.gastro.2004.12.049 (Pubitemid 40585366)
40. Poynard T., Ratziu V., McHutchison J., Manns M., Goodman Z., Zeuzem S., Younossi Z., Albrecht J., Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 2003 38 1 75 85 2-s2.0-0038122773 10.1053/jhep.2003.50267 (Pubitemid 36775798)
41. Hui J. M., Sud A., Farrell G. C., Bandara P., Byth K., Kench J. G., McCaughan G. W., George J., Insulin resistance is associated with chronic hepatitis C and virus infection fibrosis progression. Gastroenterology 2003 125 6 1695 1704 2-s2.0-0345655291 10.1053/j.gastro.2003.08.032 (Pubitemid 37500434)
42. Hourigan L. F., Macdonald G. A., Purdie D., Whitehall V. H., Shorthouse C., Clouston A., Powell E. E., Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology 1999 29 4 1215 1219 2-s2.0-0032924020 (Pubitemid 29168757)
43. Eslam M., Aparcero R., Kawaguchi T., Del Campo J. A., Sata M., Khattab M. A., Romero-Gomez M., Meta-analysis: Insulin resistance and sustained virological response in hepatitis C. Alimentary Pharmacology and Therapeutics 2011 34 3 297 305 2-s2.0-79959945801 10.1111/j.1365-2036.2011.04716.x
44. Deltenre P., Louvet A., Lemoine M., Impact of insulin resistance on sustained response in HCV patients treated with pegylated interferon and ribavirin: a meta-analysis. Journal of Hepatology 2011 55 6 1187 1194
45. Yano M., Ikeda M., Abe K. I., Dansako H., Ohkoshi S., Aoyagi Y., Kato N., Comprehensive analysis of the effects of ordinary nutrients on hepatitis C virus RNA replication in cell culture. Antimicrobial Agents and Chemotherapy 2007 51 6 2016 2027 2-s2.0-34250202525 10.1128/AAC.01426-06 (Pubitemid 46903089)
46. Abu-Mouch S., Fireman Z., Jarchovsky J., Zeina A. R., Assy N., Vitamin D supplementation improves sustained virologic response in chronic hepatitis C, (genotype 1)-naive patients. World Journal of Gastroenterology 2011 17 47 5184 5190
47. Yasutake K., Ichinose M., Bekki M., Significance of dietary intake during combined peg-interferon plus ribavirin therapy for chronic hepatitis C: relationship between polyunsaturated fatty acid and early virologic response Journal of the Japan Dietetic Association 2012 55 1 32 39
48. Leu G. Z., Lin T. Y., Hsu J. T. A., Anti-HCV activities of selective polyunsaturated fatty acids. Biochemical and Biophysical Research Communications 2004 318 1 275 280 2-s2.0-1942489017 10.1016/j.bbrc.2004.04.019 (Pubitemid 38526276)
49. Kapadia S. B., Chisari F. V., Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acids. Proceedings of the National Academy of Sciences of the United States of America 2005 102 7 2561 2566 2-s2.0-14044265120 10.1073/pnas.0409834102 (Pubitemid 40279416)
50. Vitaglione P., Fogliano V., Stingo S., Scalfi L., Capraso N., Morisco F., Development of a tomato-based food for special medical purposes as therapy adjuvant for patients with. European Journal of Clinical Nutrition 2007 61 7 906 915 2-s2.0-34447252549 10.1038/sj.ejcn.1602571 (Pubitemid 47040315)
51. Seeff L. B., Curto T. M., Szabo G., Everson G. T., Bonkovsky H. L., Dienstag J. L., Shiftman M. L., Lindsay K. L., Lok A. S. F., Di Bisceglie A. M., Lee W. M., Ghany M. G., Herbal product use by persons enrolled in the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial. Hepatology 2008 47 2 605 612 2-s2.0-39549094030 10.1002/hep.22044 (Pubitemid 351280729)
52. Bonkovsky H. L., Banner B. F., Rothman A. L., Iron and chronic viral hepatitis. Hepatology 1997 25 3 759 768 2-s2.0-0031044019 10.1002/hep.510250345 (Pubitemid 27106467)
53. Di Bisceglie A. M., Axiotis C. A., Hoofnagle J. H., Bacon B. R., Measurements of iron status in patients with chronic hepatitis. Gastroenterology 1992 102 6 2108 2113 2-s2.0-0026504010
54. Piperno A., D'Alba R., Fargion S., Roffi L., Sampietro M., Parma S., Arosio V., Fare M., Fiorelli G., Liver iron concentration in chronic viral hepatitis: a study of 98 patients. European Journal of Gastroenterology and Hepatology 1995 7 12 1203 1208 2-s2.0-0029611170 (Pubitemid 26030857)
55. Haque S., Chandra B., Gerber M. A., Lok A. S. F., Iron overload in patients with chronic hepatitis C: a clinicopathologic study. Human Pathology 1996 27 12 1277 1281 2-s2.0-0029834842 10.1016/S0046-8177(96)90337-8 (Pubitemid 26415319)
56. Di Bisceglie A. M., Bonkovsky H. L., Chopra S., Flamm S., Reddy R. K., Grace N., Killenberg P., Hunt C., Tamburro C., Tavill A. S., Ferguson R., Krawitt E., Banner B., Bacon B. R., Iron reduction as an adjuvant to interferon therapy in patients with chronic hepatitis C who have previously not responded to interferon: a multicenter, prospective, randomized, controlled trial. Hepatology 2000 32 1 135 138 2-s2.0-0034235427 (Pubitemid 30432378)
57. Erhardt A., Maschner-Olberg A., Mellenthin C., Kappert G., Adams O., Donner A., Willers R., Niederau C., Häussinger D., HFE mutations and chronic hepatitis C: H63D and C282Y heterozygosity are independent risk factors for liver fibrosis and cirrhosis. Journal of Hepatology 2003 38 3 335 342 2-s2.0-0037336495 10.1016/S0168-8278(02)00415-4 (Pubitemid 36286547)
58. Bonkovsky H. L., Troy N., McNeal K., Banner B. F., Sharma A., Obando J., Mehta S., Koff R. S., Liu Q., Hsieh C. C., Iron and HFE or TfR1 mutations as comorbid factors for development and progression of chronic hepatitis C. Journal of Hepatology 2002 37 6 848 854 2-s2.0-0036893631 10.1016/S0168-8278(02)00305-7 (Pubitemid 35404226)
59. Fontana R. J., Israel J., LeClair P., Banner B. F., Tortorelli K., Grace N., Levine R. A., Fiarman G., Thiim M., Tavill A. S., Bonkovsky H. L., Iron reduction before and during interferon therapy of chronic hepatitis C: results of a multicenter, randomized, controlled trial. Hepatology 2000 31 3 730 736 2-s2.0-17544383347 (Pubitemid 30118643)
60. Kato J., Miyanishi K., Kobune M., Nakamura T., Takada K., Takimoto R., Kawano Y., Takahashi S., Takahashi M., Sato Y., Takayama T., Niitsu Y., Long-term phlebotomy with low-iron diet therapy lowers risk of development of hepatocellular carcinoma from chronic hepatitis C. Journal of Gastroenterology 2007 42 10 830 836 2-s2.0-35448952080 10.1007/s00535-007-2095-z (Pubitemid 47617461)
61. Mendenhall C. L., Moritz T. E., Roselle G. A., Morgan T. R., Nemchausky B. A., Tamburro C. H., Schiff E. R., McClain C. J., Marsano L. S., Allen J. I., Samanta A., Weesner R. E., Henderson W., Gartside P., Chen T. S., French S. W., Chedid A., Day D., Fricke N. E., A study of oral nutritional support with oxandrolone in malnourished patients with alcoholic hepatitis: results of a Department of Veterans Affairs cooperative study. Hepatology 1993 17 4 564 576 2-s2.0-0027513259 (Pubitemid 23115499)
62. Richardson R. A., Davidson H. I., Hinds A., Cowan S., Rae P., Garden O. J., Influence of the metabolic sequelae of liver cirrhosis on nutritional intake. American Journal of Clinical Nutrition 1999 69 2 331 337 2-s2.0-0032922811 (Pubitemid 29065559)
63. Campillo B., Richardet J. P., Scherman E., Bories P. N., Evaluation of nutritional practice in hospitalized cirrhotic patients: results of a prospective study. Nutrition 2003 19 6 515 521 2-s2.0-0038100248 10.1016/S0899-9007(02)01071-7 (Pubitemid 36627435)
64. Merli M., Nutritional status in cirrhosis. Journal of Hepatology 1994 21 3 317 325 2-s2.0-0027941120 10.1016/S0168-8278(05)80308-3 (Pubitemid 24308753)
65. Tajika M., Kato M., Mohri H., Miwa Y., Kato T., Ohnishi H., Moriwaki H., Prognostic value of energy metabolism in patients with viral liver cirrhosis. Nutrition 2002 18 3 229 234 2-s2.0-0036194734 10.1016/S0899-9007(01)00754-7 (Pubitemid 34204133)
66. Owen O. E., Reichle F. A., Mozzoli M. A., Hepatic, gut, and renal substrate flux rates in patients with hepatic cirrhosis. Journal of Clinical Investigation 1981 68 1 240 252 2-s2.0-0019408539 (Pubitemid 11048096)
67. Nielsen K., Kondrup J., Martinsen L., Stilling B., Wikman B., Nutritional assessment and adequacy of dietary intake in hospitalized patients with alcoholic liver cirrhosis. British Journal of Nutrition 1993 69 3 665 679 2-s2.0-0027288195 (Pubitemid 23202470)
68. Campillo B., Bories P. N., Leluan M., Pornin B., Devanlay M., Fouet P., Short-term changes in energy metabolism after 1 month of a regular oral diet in severely malnourished cirrhotic patients. Metabolism: Clinical and Experimental 1995 44 6 765 770 2-s2.0-0029018382 10.1016/0026-0495(95)90190-6
69. Muto Y., Sato S., Watanabe A., Moriwaki H., Suzuki K., Kato A., Kato M., Nakamura T., Higuchi K., Nishiguchi S., Kumada H., Ohashi Y., Overweight and obesity increase the risk for liver cancer in patients with liver cirrhosis and long-term oral supplementation with branched-chain amino acid granules inhibits liver carcinogenesis in heavier patients with liver cirrhosis. Hepatology Research 2006 35 3 204 214 2-s2.0-33745727871 10.1016/j.hepres.2006.04.007
70. Yasutake K., Bekki M., Ichinose M., Assessing current nutritional status of patients with HCV-related liver cirrhosis in the compensated stage. Asia Pacific Journal of Clinical Nutrition 2012 21 3 400 405
71. Plauth M., Cabré E., Riggio O., Assis-Camilo M., Pirlich M., Kondrup J., Ferenci P., Holm E., vom Dahl S., Müller M. J., Nolte W., ESPEN guidelines on enteral nutrition: liver disease. Clinical Nutrition 2006 25 2 285 294 2-s2.0-33744531821 10.1016/j.clnu.2006.01.018 (Pubitemid 43811683)
72. Kato M., Miwa Y., Tajika M., Hiraoka T., Muto Y., Moriwaki H., Preferential use of branched-chain amino acids as an energy substrate in patients with liver cirrhosis. Internal Medicine 1998 37 5 429 434 2-s2.0-0032058977 (Pubitemid 128520846)
73. Shiraki M., Shimomura Y., Miwa Y., Fukushima H., Murakami T., Tamura T., Tamura N., Moriwaki H., Activation of hepatic branched-chain -keto acid dehydrogenase complex by tumor necrosis factor- in rats. Biochemical and Biophysical Research Communications 2005 328 4 973 978 2-s2.0-13744259802 10.1016/j.bbrc.2005.01.047 (Pubitemid 40238732)
74. Swart G. R., Zillikens M. C., Van Vuure J. K., Van Den Berg J. W. O., Effect of a late evening meal on nitrogen balance in patients with cirrhosis of the liver. British Medical Journal 1989 299 6709 1202 1203 2-s2.0-0024459950 (Pubitemid 19281169)
75. Zillikens M. C., Van Den Berg J. W. O., Wattimena J. L. D., Rietveld T., Swart G. R., Nocturnal oral glucose supplementation. The effects on protein metabolism in cirrhotic patients and in healthy controls. Journal of Hepatology 1993 17 3 377 383 2-s2.0-0027154934 (Pubitemid 23134937)
76. Yamauchi M., Takeda K., Sakamoto K., Ohata M., Toda G., Effect of oral branched chain amino acid supplementation in the late evening on the nutritional state of patients with liver cirrhosis. Hepatology Research 2001 21 3 199 204 2-s2.0-0035152566 10.1016/S1386-6346(01)00105-X (Pubitemid 33061717)
77. Tsuchiya M., Sakaida I., Okamoto M., Okita K., The effect of a late evening snack in patients with liver cirrhosis. Hepatology Research 2005 31 2 95 103 2-s2.0-15044347824 10.1016/j.hepres.2004.11.009 (Pubitemid 40378714)
78. Nakaya Y., Okita K., Suzuki K., Moriwaki H., Kato A., Miwa Y., Shiraishi K., Okuda H., Onji M., Kanazawa H., Tsubouchi H., Kato S., Kaito M., Watanabe A., Habu D., Ito S., Ishikawa T., Kawamura N., Arakawa Y., BCAA-enriched snack improves nutritional state of cirrhosis. Nutrition 2007 23 2 113 120 2-s2.0-33846206486 10.1016/j.nut.2006.10.008 (Pubitemid 46096726)
79. Aoyama K., Tsuchiya M., Mori K., Kubo Y., Shiraishi K., Sakaguchi E., Yamashita S., Sakaida I., Effect of a late evening snack on outpatients with liver cirrhosis. Hepatology Research 2007 37 8 608 614 2-s2.0-34347363025 10.1111/j.1872-034X.2007.00036.x (Pubitemid 47009246)
80. Chang W. K., Chao Y. C., Tang H. S., Lang H. F., Hsu C. T., Effects of extra-carbohydrate supplementation in the late evening on energy expenditure and substrate oxidation in patients with liver cirrhosis. Journal of Parenteral and Enteral Nutrition 1997 21 2 96 99 2-s2.0-0030964899
81. Yamanaka-Okumura H., Nakamura T., Takeuchi H., Miyake H., Katayama T., Arai H., Taketani Y., Fujii M., Shimada M., Takeda E., Effect of late evening snack with rice ball on energy metabolism in liver cirrhosis. European Journal of Clinical Nutrition 2006 60 9 1067 1072 2-s2.0-33748434464 10.1038/sj.ejcn.1602420 (Pubitemid 44340405)
82. Miwa Y., Shiraki M., Kato M., Tajika M., Mohri H., Murakami N., Kato T., Ohnishi H., Morioku T., Muto Y., Moriwaki H., Improvement of fuel metabolism by nocturnal energy supplementation in patients with liver cirrhosis. Hepatology Research 2000 18 3 184 189 2-s2.0-0033819329 10.1016/S1386-6346(99)00100-X
83. Yatsuhashi H., Ohnishi Y., Nakayama S., Anti-hypoalbuminemic effect of branched-chain amino acid granules in patients with liver cirrhosis is independent of dietary energy and protein intake. Hepatology Research 2011 41 11 1027 1035
84. Marchesini G., Bianchi G., Merli M., Amodio P., Panella C., Loguercio C., Fanelli F. R., Abbiati R., Nutritional supplementation with branched-chain amino acids in advanced cirrhosis: a double-blind, randomized trial. Gastroenterology 2003 124 7 1792 1801 2-s2.0-0038047688 10.1016/S0016-5085(03) 00323-8 (Pubitemid 36666776)
85. Poon R. T. P., Yu W. C., Fan S. T., Wong J., Long-term oral branched chain amino acids in patients undergoing chemoembolization for hepatocellular carcinoma: a randomized trial. Alimentary Pharmacology and Therapeutics 2004 19 7 779 788 2-s2.0-1942534222 10.1111/j.1365-2036.2004.01920.x (Pubitemid 38496644)
86. Kato A., Suzuki K., How to select BCAA preparations. Hepatology Research 2004 30 S30 S35 2-s2.0-11144322362 10.1016/j.hepres.2004.08.008 (Pubitemid 40028806)
87. Imano E., Kanda T., Nakatani Y., Motomura M., Arai K., Matsuhisa M., Yamasaki Y., Hori M., Impaired splanchnic and peripheral glucose uptake in liver cirrhosis. Journal of Hepatology 1999 31 3 469 473 2-s2.0-0033199752 10.1016/S0168-8278(99)80039-7 (Pubitemid 29408730)
88. Petrides A. S., Stanley T., Matthews D. E., Vogt C., Bush A. J., Lambeth H., Insulin resistance in cirrhosis: prolonged reduction of hyperinsulinemia normalizes insulin sensitivity. Hepatology 1998 28 1 141 149 2-s2.0-0031807404 10.1002/hep.510280119 (Pubitemid 28299995)
89. Barkoukis H., Fiedler K. M., Lerner E., A combined high-fiber, low-glycemic index diet normalizes glucose tolerance and reduces hyperglycemia and hyperinsulinemia in adults with hepatic cirrhosis. Journal of the American Dietetic Association 2002 102 10 1503 1507 2-s2.0-15944427871 10.1016/S0002-8223(02)90334-2 (Pubitemid 40445691)
90. Jenkins D. J. A., Shapira N., Greenberg G., Jenkins A. L., Collier G. R., Poduch C., Wolever T. M. S., Anderson G. H., Blendis L. M., Low glycemic index foods and reduced glucose, amino acid, and endocrine responses in cirrhosis. American Journal of Gastroenterology 1989 84 7 732 739 2-s2.0-0024320508 (Pubitemid 19184373)
91. Gentile S., Turco S., Guarino G., Oliviero B., Annunziata S., Cozzolino D., Sasso F. C., Turco A., Salvatore T., Torella R., Effect of treatment with acarbose and insulin in patients with non-insulin-dependent diabetes mellitus associated with non-alcoholic liver cirrhosis. Diabetes, Obesity and Metabolism 2001 3 1 33 40 2-s2.0-0034872965 10.1046/j.1463-1326.2001.00103.x (Pubitemid 32782851)
92. Zillikens M. C., Swart G. R., Van den Berg J. W. O., Wilson J. H. P., Effects of the glucosidase inhibitor acarbose in patients with liver cirrhosis. Alimentary Pharmacology and Therapeutics 1989 3 5 453 459 2-s2.0-0024918078 (Pubitemid 20116265)
93. Marchesini G., Bugianesi E., Ronchi M., Flamia R., Thomaseth K., Pacini G., Zinc supplementation improves glucose disposal in patients with cirrhosis. Metabolism: Clinical and Experimental 1998 47 7 792 798 2-s2.0-0031837619 10.1016/S0026-0495(98)90114-7 (Pubitemid 28313183)
94. Córdoba J., López-Hellín J., Planas M., Sabín P., Sanpedro F., Castro F., Esteban R., Guardia J., Normal protein diet for episodic hepatic encephalopathy: results of a randomized study. Journal of Hepatology 2004 41 1 38 43 2-s2.0-3442901065 10.1016/j.jhep.2004.03.023 (Pubitemid 39005150)
95. Sharma P., Sharma B. C., Puri V., Sarin S. K., An open-label randomized controlled trial of lactulose and probiotics in the treatment of minimal hepatic encephalopathy. European Journal of Gastroenterology and Hepatology 2008 20 6 506 511 2-s2.0-43449114798 10.1097/MEG.0b013e3282f3e6f5 (Pubitemid 351667890)
96. Reding P., Duchateau J., Bataille C., Oral zinc supplementation improves hepatic encephalopathy. Results of a randomised controlled trial. Lancet 1984 2 8401 493 495 2-s2.0-0021176374 (Pubitemid 14069766)
97. Takuma Y., Nousot K., Makino Y., Hayashi M., Takahashi H., Clinical trial: oral zinc in hepatic encephalopathy. Alimentary Pharmacology and Therapeutics 2010 32 9 1080 1090 2-s2.0-78449271709 10.1111/j.1365-2036.2010. 04448.x
98. Calle E. E., Rodriguez C., Walker-Thurmond K., Thun M. J., Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. Adults. The New England Journal of Medicine 2003 348 17 1625 1638 2-s2.0-0037464510 10.1056/NEJMoa021423 (Pubitemid 36459468)
99. Nishitani S., Takehana K., Fujitani S., Sonaka I., Branched-chain amino acids improve glucose metabolism in rats with liver cirrhosis. American Journal of Physiology 2005 288 6 G1292 G1300 2-s2.0-19644382955 10.1152/ajpgi.00510.2003 (Pubitemid 40741084)
100. Fukushima H., Miwa Y., Shiraki M., Gomi I., Toda K., Kuriyama S., Nakamura H., Wakahara T., Era S., Moriwaki H., Oral branched-chain amino acid supplementation improves the oxidized/ reduced albumin ratio in patients with liver cirrhosis. Hepatology Research 2007 37 9 765 770 2-s2.0-34447301490 10.1111/j.1872-034X.2007.00123.x (Pubitemid 47054783)
101. Ohno T., Tanaka Y., Sugauchi F., Orito E., Hasegawa I., Nukaya H., Kato A., Matunaga S., Endo M., Tanaka Y., Sakakibara K., Mizokami M., Suppressive effect of oral administration of branched-chain amino acid granules on oxidative stress and inflammation in HCV-positive patients with liver cirrhosis. Hepatology Research 2008 38 7 683 688 2-s2.0-44649113152 10.1111/j.1872-034X. 2008.00319.x (Pubitemid 351784981)